Shanghai Rightongene Biotechnology Co., Ltd. (SHA:688217)
29.55
-0.62 (-2.06%)
At close: Mar 9, 2026
SHA:688217 Revenue
In the year 2025, Shanghai Rightongene Biotechnology had annual revenue of 174.00M CNY, down -28.19%. Shanghai Rightongene Biotechnology had revenue of 34.90M in the quarter ending December 31, 2025, a decrease of -36.37%.
Revenue
174.00M
Revenue Growth
-28.19%
P/S Ratio
9.82
Revenue / Employee
433.91K
Employees
385
Market Cap
1.71B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Tiansheng Pharmaceutical Group | 516.17M |
| Sailong Pharmaceutical Group | 244.84M |
| Hunan Nucien Pharmaceutical | 141.93M |
| Jiangsu Gdk Biological Technology | 113.23M |
| Hubei Goto Biopharm | 626.28M |
| Guiyang Xintian Pharmaceutical | 755.34M |
| Jiangsu CoWin Biotech | 193.05M |
| Zhejiang East Asia Pharmaceutical | 831.56M |